$DFCO
DALRADA FINANCIAL CORP Stock $dfco

$dfco Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000168316823007283 Filed on October 19, 2023

Income Statement

Concept	2023 Q4	2023 Q2	2023
Revenue	$6.078M	$10.75M	$29.74M
YoY Change	15.7%	196.58%	54.35%
Cost Of Revenue	$4.076M	$8.755M	$20.68M
YoY Change	37.93%	134.91%	136.03%
Gross Profit	$2.002M	$1.998M	$9.060M
YoY Change	-12.89%	-2076.54%	-13.77%
Gross Profit Margin	32.94%	18.58%	30.46%
Selling, General & Admin	$6.227M	$10.85M	$29.47M
YoY Change	-12.04%	174.36%	46.84%
% of Gross Profit	311.1%	542.91%	325.24%
Research & Development		$120.0K	$120.0K
YoY Change		-81.69%	-81.74%
% of Gross Profit		6.0%	1.32%
Depreciation & Amortization	$127.8K	$177.4K	$360.5K
YoY Change	0.0%	6.78%	42.54%
% of Gross Profit	6.38%	8.88%	3.98%
Operating Expenses	$6.227M	$11.15M	$30.02M
YoY Change	-12.04%	134.21%	43.35%
Operating Profit	-$4.226M	-$9.149M	-$20.96M
YoY Change	-11.64%	88.23%	100.86%
Interest Expense	$214.0K	-$249.3K	$2.553M
YoY Change	-82.47%	-62.28%	95.82%
% of Operating Profit
Other Income/Expense, Net	-$1.215M	$902.2K	$332.2K
YoY Change	-504.94%	166.96%	-133.09%
Pretax Income	-$5.440M	-$8.930M	-$20.63M
YoY Change	21.37%	65.31%	80.32%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$5.406M	-$8.236M	-$20.29M
YoY Change	22.51%	63.93%	43.94%
Net Earnings / Revenue	-88.95%	-76.59%	-68.24%
Basic Earnings Per Share	-$0.06		-$0.24
Diluted Earnings Per Share	-$0.06	-$0.09	-$0.24
COMMON SHARES
Basic Shares Outstanding	89.93M shares	88.70M shares	83.76M shares
Diluted Shares Outstanding	89.96M shares		83.76M shares

Balance Sheet

Concept	2023 Q4	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$598.4K	$812.8K
YoY Change	-46.09%	-8.86%
Cash & Equivalents	$598.4K	$812.8K
Short-Term Investments
Other Short-Term Assets	$668.9K	$1.343M	$1.340M
YoY Change	6.58%	212.39%	211.58%
Inventory	$2.570M	$2.079M	$2.080M
Prepaid Expenses
Receivables	$5.489M	$4.453M	$6.020M
Other Receivables	$1.240M	$376.6K	$370.0K
Total Short-Term Assets	$11.49M	$9.817M	$9.820M
YoY Change	11.16%	2.65%	2.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.623M	$1.476M	$6.480M
YoY Change	6.24%	37.13%	69.23%
Goodwill	$3.803M	$3.803M
YoY Change	-10.59%	-10.59%
Intangibles	$3.655M	$3.858M
YoY Change	-2.29%	9.45%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.93M	$15.35M	$15.35M
YoY Change	1.43%	19.39%	19.37%
TOTAL ASSETS
Total Short-Term Assets	$11.49M	$9.817M	$9.820M
Total Long-Term Assets	$14.93M	$15.35M	$15.35M
Total Assets	$26.43M	$25.17M	$25.17M
YoY Change	5.45%	12.25%	12.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.554M	$5.179M	$5.730M
YoY Change	117.67%	122.09%	145.72%
Accrued Expenses	$920.2K	$1.084M	$2.260M
YoY Change	-73.54%	-39.76%	-51.5%
Deferred Revenue		$1.337M
YoY Change		85.49%
Short-Term Debt	$0.00	$251.6K	$250.0K
YoY Change	-100.0%	-97.66%	-97.68%
Long-Term Debt Due	$439.6K	$439.6K	$440.0K
YoY Change	-36.04%	-34.3%	-34.23%
Total Short-Term Liabilities	$14.18M	$10.02M	$10.02M
YoY Change	-48.09%	-50.93%	-50.92%
LONG-TERM LIABILITIES
Long-Term Debt	$7.284M	$2.709M	$2.710M
YoY Change	-22.89%	-73.28%	-73.27%
Other Long-Term Liabilities	$7.898M	$8.188M	$8.190M
YoY Change	1.05%	20.05%	20.08%
Total Long-Term Liabilities	$15.18M	$10.90M	$10.90M
YoY Change	-12.05%	-35.75%	-35.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.18M	$10.02M	$10.02M
Total Long-Term Liabilities	$15.18M	$10.90M	$10.90M
Total Liabilities	$29.36M	$20.92M	$21.06M
YoY Change	-34.13%	-44.04%	-44.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.0M	-$141.7M
YoY Change	17.37%	16.71%
Common Stock	$471.4K	$443.5K
YoY Change	10.08%	22.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.020M	$4.109M	$4.110M
YoY Change
Total Liabilities & Shareholders Equity	$26.43M	$25.17M	$25.17M
YoY Change	5.45%	12.25%	12.25%

Cashflow Statement

Concept	2023 Q4	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$5.406M	-$8.236M	-$20.29M
YoY Change	22.51%	63.93%	43.94%
Depreciation, Depletion And Amortization	$127.8K	$177.4K	$360.5K
YoY Change	0.0%	6.78%	42.54%
Cash From Operating Activities	-$1.720M	$5.462M	-$4.613M
YoY Change	-53.57%	-296.23%	-55.43%
INVESTING ACTIVITIES
Capital Expenditures	$200.9K	$205.4K	$693.2K
YoY Change	-64.24%	-187.55%	8.28%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$20.36K	$100.0K
YoY Change	-100.0%	-93.39%	-67.55%
Cash From Investing Activities	-$200.9K	-$185.1K	-$1.063M
YoY Change	-59.07%	-351.64%	85.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.222M	-5.723M	$5.717M
YoY Change	-43.39%	-287.5%	-51.0%
NET CHANGE
Cash From Operating Activities	-1.720M	5.462M	-$4.613M
Cash From Investing Activities	-200.9K	-185.1K	-$1.063M
Cash From Financing Activities	2.222M	-5.723M	$5.717M
Net Change In Cash	301.8K	-446.5K	$40.92K
YoY Change	-212.08%	-230.38%	-94.51%
FREE CASH FLOW
Cash From Operating Activities	-$1.720M	$5.462M	-$4.613M
Capital Expenditures	$200.9K	$205.4K	$693.2K
Free Cash Flow	-$1.920M	$5.256M	-$5.306M
YoY Change	-54.98%	-306.23%	-51.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000725394
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability		usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
CY2022	DFCO	Stock Consideration Issued To Vendor StockConsiderationIssuedToVendor		usd
CY2022	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability		usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest		usd
CY2023	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-12641
CY2023	dei	Entity Registrant Name EntityRegistrantName	DALRADA FINANCIAL CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3713274
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	600 La Terraza Blvd.
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Escondido
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92025
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	283-1253
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.005 par value per share
CY2023	dei	Trading Symbol TradingSymbol	DFCO
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	6009387	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89933776	shares
CY2023	dei	Auditor Name AuditorName	Macias Gini & O’Connell LLP
CY2023	dei	Auditor Location AuditorLocation	Melville, New York
CY2023	dei	Auditor Firm AuditorFirmId	324
CY2022	dei	Auditor Name AuditorName	dbbmckennon
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022	dei	Auditor Firm AuditorFirmId	3501
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812806	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4453104	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6406555	usd
CY2023Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	752348	usd
CY2022Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	41603	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	376604	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	288655	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1343491	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	430070	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	9817045	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9563566	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41722	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2023Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1173893	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1209103	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2023Q2	us-gaap	Goodwill Goodwill	3803147	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4253424	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3858086	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3524888	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2771854	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1665436	usd
CY2023Q2	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	2227286	usd
CY2022Q2	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	1087256	usd
CY2023Q2	us-gaap	Assets Assets	25169115	usd
CY2022Q2	us-gaap	Assets Assets	22422480	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5178897	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2331919	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1084008	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1799404	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	0	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2055736	usd
CY2023Q2	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	547949	usd
CY2022Q2	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	1270133	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1337259	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	720923	usd
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	439562	usd
CY2022Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	669028	usd
CY2023Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	251605	usd
CY2022Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	9269377	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1495528	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	660394	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	435647	usd
CY2023Q2	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	519791	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	369050	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10019465	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20416745	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	48888	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	120534	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1011395	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2023Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	1648478	usd
CY2022Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	9538685	usd
CY2023Q2	DFCO	Contingent Consideration ContingentConsideration	4285389	usd
CY2022Q2	DFCO	Contingent Consideration ContingentConsideration	4870800	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2160834	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231691	usd
CY2023Q2	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	1741830	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	718206	usd
CY2023Q2	us-gaap	Liabilities Liabilities	20916279	usd
CY2022Q2	us-gaap	Liabilities Liabilities	37375662	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88699139	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88699139	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72174620	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72174620	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	443478	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	360855	usd
CY2023Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	192925	usd
CY2022Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	1066925	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	145251822	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104627032	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141729009	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121436490	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50848	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50673	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4109019	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-15432201	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	143817	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	479019	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4252836	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25169115	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22422480	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27456223	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17864557	usd
CY2023	DFCO	Revenues Related Party RevenuesRelatedParty	2282746	usd
CY2022	DFCO	Revenues Related Party RevenuesRelatedParty	1403056	usd
CY2023	us-gaap	Revenues Revenues	29738969	usd
CY2022	us-gaap	Revenues Revenues	19267613	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20679050	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8761266	usd
CY2023	us-gaap	Gross Profit GrossProfit	9059919	usd
CY2022	us-gaap	Gross Profit GrossProfit	10506347	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4022656	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2772770	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29466320	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20066286	usd
CY2023	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	120000	usd
CY2022	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	656997	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	433556	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	30019876	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	20941591	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-20959957	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10435244	usd
CY2023	us-gaap	Interest Expense InterestExpense	2552918	usd
CY2022	us-gaap	Interest Expense InterestExpense	1303714	usd
CY2023	us-gaap	Interest Income Operating InterestIncomeOperating	79758	usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	4451	usd
CY2023	us-gaap	Other Income OtherIncome	722620	usd
CY2022	us-gaap	Other Income OtherIncome	308534	usd
CY2023	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-8202	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-13297	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	332236	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1004026	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20627721	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11439270	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	132513	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-20627721	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11571783	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-175	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-82960	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20627896	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11654743	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-335202	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2526533	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20292519	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14098316	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83761903	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72217851	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83761903	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72217851	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13407388	usd
CY2022	DFCO	Issuance Of Preferred Stock IssuanceOfPreferredStock	6532106	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1093003	usd
CY2022	DFCO	Joint Venture JointVenture	-1950563	usd
CY2022	DFCO	Reversal Of Shares Previously Issued To Directors ReversalOfSharesPreviouslyIssuedToDirectors	-14826	usd
CY2022	DFCO	Common Stock And Warrants Issued In Connection With Convertible Note CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote	1542695	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	133664	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2772770	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-11571783	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-82960	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2023	DFCO	Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium	1447488	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	314475	usd
CY2023	DFCO	Common Stock Issued Pursuant To Consultant Agreement CommonStockIssuedPursuantToConsultantAgreement	184000	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	33859544	usd
CY2023	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	5751	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4022656	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-20627721	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-175	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4252836	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-20627721	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-11571783	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	707572	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	323018	usd
CY2023	DFCO	Share Based Compensation1 ShareBasedCompensation1	4022656	usd
CY2022	DFCO	Share Based Compensation1 ShareBasedCompensation1	2772770	usd
CY2023	DFCO	Stock Consideration Issued To Vendor StockConsiderationIssuedToVendor	184000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1224472	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	554970	usd
CY2023	DFCO	Convertible Debt Premium Satisfied With Common Stock ConvertibleDebtPremiumSatisfiedWithCommonStock	200000	usd
CY2022	DFCO	Convertible Debt Premium Satisfied With Common Stock ConvertibleDebtPremiumSatisfiedWithCommonStock	20000	usd
CY2023	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-270936	usd
CY2022	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-182200	usd
CY2023	DFCO	Bad Debt Expense BadDebtExpense	4783357	usd
CY2022	DFCO	Bad Debt Expense BadDebtExpense	1659559	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	433556	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2023	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3897875	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7383296	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	60660	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	221327	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	454071	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	608657	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	722147	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	137767	usd
CY2023	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-35883	usd
CY2022	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	1251498	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2822813	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1116618	usd
CY2023	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	-71646	usd
CY2022	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	120534	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	7936820	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	2405364	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	640529	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1211943	usd
CY2023	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	35242	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	102712	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	556336	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	500924	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4612798	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10349808	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	693201	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	640184	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	470680	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	242063	usd
CY2023	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	100454	usd
CY2022	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	308207	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1063427	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-574040	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	6757688	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	11492218	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2880000	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	350028	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-233556	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1680000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	300000	usd
CY2022	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	2120308	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	289428	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-34943	usd
CY2022	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary	14826	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5717144	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11668585	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40919	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	744737	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-175	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-82960	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110285	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	812806	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	772062	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	139941	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	77766	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	9048	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	33859544	usd
CY2022	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	6532206	usd
CY2023	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	0	usd
CY2022	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
CY2023	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	0	usd
CY2022	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	58560	usd
CY2023	DFCO	Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties	8676605	usd
CY2022	DFCO	Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties	181744	usd
CY2023	DFCO	Common Stock And Warrant Issued In Connection With Convertible Note CommonStockAndWarrantIssuedInConnectionWithConvertibleNote	0	usd
CY2022	DFCO	Common Stock And Warrant Issued In Connection With Convertible Note CommonStockAndWarrantIssuedInConnectionWithConvertibleNote	1542695	usd
CY2023	DFCO	Common Stock Issued Pursuant To Conversion Of Note Accrued Interest And Premium CommonStockIssuedPursuantToConversionOfNoteAccruedInterestAndPremium	0	usd
CY2022	DFCO	Common Stock Issued Pursuant To Conversion Of Note Accrued Interest And Premium CommonStockIssuedPursuantToConversionOfNoteAccruedInterestAndPremium	133664	usd
CY2023	DFCO	Common Stock Issued Pursuant To Business Combination CommonStockIssuedPursuantToBusinessCombination	314475	usd
CY2022	DFCO	Common Stock Issued Pursuant To Business Combination CommonStockIssuedPursuantToBusinessCombination	1093003	usd
CY2023	DFCO	Fair Value Of Assets Acquired And Liabilities Assumed In Acquisition FairValueOfAssetsAcquiredAndLiabilitiesAssumedInAcquisition	0	usd
CY2022	DFCO	Fair Value Of Assets Acquired And Liabilities Assumed In Acquisition FairValueOfAssetsAcquiredAndLiabilitiesAssumedInAcquisition	468232	usd
CY2023	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	1447488	usd
CY2022	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	0	usd
CY2023	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	2227830	usd
CY2022	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_zugXyFW22fUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zt7v7PwDwAtf">Organization and Nature of Operations</span> </b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Unless otherwise stated or the context requires otherwise, references herein to the “Company,” “Dalrada,” “we,” “us,” and “our” mean Dalrada Financial Corporation and its direct and indirect subsidiaries, and controlled and managed entities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalrada Financial Corporation, (“Dalrada”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTCQB: DFCO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalrada has five primary business divisions: <b>Genefic</b>, <b>Dalrada Energy Services</b>, <b>Dalrada Precision Manufacturing</b>, <b>Dalrada Technologies </b>and <b>Dalrada Corporate</b>. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><span style="text-decoration: underline">Genefic (formerly Dalrada Health)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Genefic, formerly named Dalrada Health, delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, this specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Empower Genomics (“Empower”)</b>- Empower is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Empower has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Empower also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pala Diagnostics (“Pala”)</b>- Pala is a joint venture diagnostic laboratory which processes both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Solas Corp. (“Solas”)</b>- Solas manages and oversees wellness clinics throughout Southern California including the Sòlas Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic enhancements amongst a myriad of additional health centric services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>International Health Group (“IHG”)</b>- IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pacific Stem Cells (“PSC”)</b>- PSC markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based products (HCT/Ps).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Watson Rx Solutions (“Watson”)</b>- In June 2022, the Company acquired Watson, an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Watson helps manage disease states through education and prescription management while offering generic as well as specialty medications. Watson maintains pharmacy licenses in all 50 States including Washington D.C.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>GlanHealth (“GlanHealth”)</b>- Genefic Products launched GlanHealth in 2020 to distribute alcohol-free hand sanitizers, surface cleaners, laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, kits, and delivery equipment such as dispensers, stands, and ease of use packaging for the end consumer. GlanHealth leverages an extensive supply chain of producers, resellers, distributors, vendors, and formulators for the development, sale, and marketing of its products and services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><span style="text-decoration: underline">Dalrada Energy Services</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalrada Energy Services (‘DES’) employs next-generation technology that enhances clean energy efforts while reducing the world’s carbon footprint. Through innovative products and commercial services, DES facilitates energy transition for universities, businesses, government buildings, and more.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Energy Services Inc. (“DES”)</b>- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity, DES helps organizations meet environmental, social, and governance (“ESG”) goals and standards while mitigating negative environmental impacts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Bothof Brothers Construction (“Bothof”)</b>- The Company acquired Bothof in November 2022. Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division is able to provide a myriad of additional services to its private and public works customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><span style="text-decoration: underline">Dalrada Precision Manufacturing</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Precision Parts (“Precision”)</b>- Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Likido Ltd. (“Likido”)</b>- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and the minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Ignite I.T. (“Ignite”)</b>- Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meet or exceed the most stringent industry-testing specifications. Ignites products are effective and available solutions to the increased demand for protecting employees from hazardous chemicals currently used and highlighted in recent federal and state regulations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Deposition Technologies (“DepTec”)</b>- Dalrada Precision Manufacturing acquired DepTec in April 2022. DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white">DepTec has built a multitude of precision OEM parts for PVD (Physical vapor deposition) and refurbished systems which allow clients the option of purchasing the same model of system they’ve been using for decades – but with upgrades and improved efficiencies. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs and expect to meet the increased US market demand driven by the CHIPS and Science Act of 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Technology Limited (“DTL”)- </b>Dalrada Precision Manufacturing Inc. entered into an Ownership Purchase Agreement to purchase all of the membership interests in Dalrada Technology Limited on March 1, 2023. DTL is a holding company for all European based Dalrada Precision entities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Technology Spain L.T. (“DTS”)- </b>DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the Company’s heat pump technology throughout Europe.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><span style="text-decoration: underline">Dalrada Technologies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Prakat (“Prakat”)</b>- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><span style="text-decoration: underline">Dalrada Corporate</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Dalrada Corporate covers activities which support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal advice, information technology, and marketing. It also contains executive management and shareholder-related services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i><span style="text-decoration: underline">Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">These consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of June 30, 2023, and 2022, the Company had a working capital deficit of $<span id="xdx_90E_ecustom--WorkingCapital_iNI_di_c20230630_zgzsfsHI7fG8" title="Working capital deficit">202,420</span> and $ $<span id="xdx_906_ecustom--WorkingCapital_iNI_di_c20220630_zYThloXatjHi" title="Working capital deficit">9,357,651</span>, respectively. The Company incurred negative cash flows from operations for the years ended June 30, 2023, and 2022, and raises substantial doubt about the Company’s ability to continue as a going concern. The continuation of the Company as a going concern is dependent upon the successful financing through equity and/or debt investors and growing the subsidiaries anticipated to be profitable while reducing investments in areas that are not expected to have long-term benefits. The Company expects to fund any short-term operational deficits primarily through collection of outstanding accounts receivable from medical insurance providers, Medicare, pharmaceutical sales, the sale of Likido units as well as loans from related parties.</p>
CY2023Q2	DFCO	Working Capital WorkingCapital	-202420	usd
CY2022Q2	DFCO	Working Capital WorkingCapital	-9357651	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zSvXMKxVSEsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_ztPXL8yu01b">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of these consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, litigation, and evaluation of goodwill and intangible assets for impairment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zf3k7nD7uPXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_860_zVtpFlWHnrH6">Concentrations of Credit Risk</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">When estimating its allowance for credit losses related to revenues from Covid Testing, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Management considers various historical collection factors for assessing collectability and determining net revenues and accounts receivable from our customers which include the period that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended June 30, 2023 and 2022, healthcare insurers and government payers accounted for over <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersAndGovernmentPayersMember_z6mx8ai4R775" title="Concentrations of credit risk">42</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zyuT8eqnA0Ke" title="Concentrations of credit risk">61</span>% of total revenues, respectively. Also, healthcare insurers and government payers amounted to total revenues of $<span id="xdx_901_eus-gaap--Revenues_pp0p0_c20220701__20230630__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zj54G3LFzV27" title="Revenues">12,546,849</span> and $<span id="xdx_903_eus-gaap--Revenues_pp0p0_c20210701__20220630__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zKLpxY02iP78" title="Revenues">11,824,717</span> for the years ended June 30, 2023 and 2022, respectively. The accounts receivable related to both healthcare insurers and government payers is $<span id="xdx_909_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20230630__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_z65x3xpXxPo3" title="Accounts receivable">1,499,415</span> and $<span id="xdx_903_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20220630__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zxtRdUGsK7o6" title="Accounts receivable">4,129,953</span> as of June 30, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the year ended June 30, 2023, DES’s Averett University project accounted for $<span id="xdx_90A_eus-gaap--Revenues_pp0p0_c20220701__20230630__srt--MajorCustomersAxis__custom--AverettUniversaryMember_zOhPnZKTLRrk" title="Revenues">3,741,494</span>, or <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AverettUniversaryMember_zkyCAwlMD8h3" title="Concentrations of credit risk">12</span>% of total revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of June 30, 2023 and 2022, $<span id="xdx_90D_eus-gaap--ReceivablesFromCustomers_iI_c20230630_zeYo94tSA6l2" title="Amount owed by customers from the sale">829,239</span> and $<span id="xdx_909_eus-gaap--ReceivablesFromCustomers_iI_c20220630_z9Fa3KLMwjsg" title="Amount owed by customers from the sale">880,500</span> is owed by customers from the sale of Likido units, respectively.</p>
CY2023Q2	us-gaap	Receivables From Customers ReceivablesFromCustomers	829239	usd
CY2022Q2	us-gaap	Receivables From Customers ReceivablesFromCustomers	880500	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4285389	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4870800	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4870800	usd
CY2023	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	-585411	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4285389	usd
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	usd
CY2022	DFCO	Initial Recognition In Connection With Acquisition Of Deptec InitialRecognitionInConnectionWithAcquisitionOfDeptec	5053000	usd
CY2022	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-182200	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4870800	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	4453104	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	6406555	usd
CY2023Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	752348	usd
CY2022Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	41603	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41722	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2430615	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	119791	usd
CY2023Q2	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1173893	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1209103	usd
CY2023	DFCO	Change In Fair Value Of Contingent Consideration2 ChangeInFairValueOfContingentConsideration2	585411	usd
CY2023Q2	DFCO	Contingent Consideration ContingentConsideration	4285389	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	433556	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29738969	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19267613	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	1337259	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	720923	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20679050	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8761266	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	292473	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	560777	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4022656	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2772770	usd
CY2022	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.20
CY2021Q2	us-gaap	Goodwill Goodwill	736456	usd
CY2022	DFCO	Additions Additions	3735276	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	0.33
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Other Share Increase Decrease In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice	0.45
CY2023	DFCO	Proceeds From Anti Dilutive Shares ProceedsFromAntiDilutiveShares	15150695	usd
CY2022	DFCO	Proceeds From Anti Dilutive Shares ProceedsFromAntiDilutiveShares	5411250	usd
CY2023	DFCO	Average Stock Price AverageStockPrice	0.13
CY2022	DFCO	Average Stock Price AverageStockPrice	0.50
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	116543810	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	10822500	shares
CY2023Q2	us-gaap	Goodwill Goodwill	3803147	usd
CY2021Q3	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
CY2023Q2	DFCO	Goodwill Written Down GoodwillWrittenDown	0	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	30000	usd
CY2022Q4	DFCO	Warrant Issued WarrantIssued	3000000	shares
CY2022Q4	DFCO	Strike Price StrikePrice	0.15
CY2022Q4	DFCO	Cashless Warrants Vest CashlessWarrantsVest	450000	usd
CY2022Q4	DFCO	Cashless Warrants CashlessWarrants	6000000	usd
CY2022Q4	DFCO	Warrant Consideration WarrantConsideration	5101223	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Rate NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationRate	1	pure
CY2023Q1	DFCO	Warrant Issued WarrantIssued	1000000	shares
CY2023Q1	DFCO	Strike Price StrikePrice	0.10
CY2023Q1	DFCO	Warrant Consideration WarrantConsideration	68975	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	1000000	shares
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	33047518	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	23723570	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-23202682	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-14169496	usd
CY2023	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.28
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	658175	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	399706	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	708007	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	712510	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1224915	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1448556	usd
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	740147	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	208689	usd
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	314642	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	426162	usd
CY2022Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	518017	usd
CY2023Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	249613	usd
CY2022Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2333020	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1572806	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	856938	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	496394	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	360544	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	252937	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4253424	usd
CY2023	DFCO	Additions Additions	0	usd
CY2023	us-gaap	Business Acquisitions Purchase Price Allocation Year Of Acquisition Net Effect On Income BusinessAcquisitionsPurchasePriceAllocationYearOfAcquisitionNetEffectOnIncome	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	433556	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4253424	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3670665	usd
CY2023	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	663505	usd
CY2023	DFCO	Finite Lived Intangible Assets Adjustments To Purchase Price Allocation FiniteLivedIntangibleAssetsAdjustmentsToPurchasePriceAllocation	16721	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4350891	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	145777	usd
CY2023	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	347028	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	492805	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3858086	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	693385	usd
CY2022	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	2977280	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3670665	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28891	usd
CY2022	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	116886	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	145777	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3524888	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	347028	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	116886	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	396596	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	361280	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	299265	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	299265	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	299265	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	2202415	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3858086	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	0	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2055736	usd
CY2023	DFCO	Accrued Interest Rate AccruedInterestRate	Accrued interest was compounded daily at an estimated effective interest rate of 7.33%.
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	35242	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	30155	usd
CY2023	DFCO	Gain On Expiration Of Accrued Tax Liabilities GainOnExpirationOfAccruedTaxLiabilities	2090978	usd
CY2022	DFCO	Gain On Expiration Of Accrued Tax Liabilities GainOnExpirationOfAccruedTaxLiabilities	0	usd
CY2023Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	1900083	usd
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	14182	usd
CY2022Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	18808062	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	362855	usd
CY2023Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	251605	usd
CY2023Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	1648478	usd
CY2023Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	1900083	usd
CY2022Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	9269377	usd
CY2022Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	9538685	usd
CY2022Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	18808062	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	439562	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	669028	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1011395	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	1450957	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	1148029	usd
CY2023	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	2656	usd
CY2023Q2	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	336898	usd
CY2023Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0825	pure
CY2023	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-06-26
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10059024	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5801923	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10059024	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	600000	usd
CY2023	DFCO	Redemption Premium In Cash RedemptionPremiumInCash	280000	usd
CY2022	DFCO	Redemption Premium In Cash RedemptionPremiumInCash	60000	usd
CY2023	DFCO	Redemption Premium In Stock RedemptionPremiumInStock	200000	usd
CY2022	DFCO	Redemption Premium In Stock RedemptionPremiumInStock	20000	usd
CY2023	DFCO	Debenture In Cash DebentureInCash	1400000	usd
CY2022	DFCO	Debenture In Cash DebentureInCash	300000	usd
CY2023	DFCO	Debenture In Stock DebentureInStock	1000000	usd
CY2022	DFCO	Debenture In Stock DebentureInStock	300000	usd
CY2023	DFCO	Revenues Related Party RevenuesRelatedParty	2282746	usd
CY2022	DFCO	Revenues Related Party RevenuesRelatedParty	1403056	usd
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.59
CY2022Q1	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	1338644	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.41
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	250000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.08
CY2023Q2	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	2143402	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.10
CY2023Q2	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	47408	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y10M13D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11025000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.45
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12025000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M25D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	33426134	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.29
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	45451134	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M29D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	23281917	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.39
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y5M12D
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5801923	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4022656	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2772770	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4985051	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1690423	usd
CY2023	us-gaap	Revenues Revenues	29738969	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-20959957	usd
CY2022	us-gaap	Revenues Revenues	19267613	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-10435244	usd
CY2023	us-gaap	Revenues Revenues	29738969	usd
CY2022	us-gaap	Revenues Revenues	19267613	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1395435	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1294901	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1254653	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1232993	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	431085	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	32627	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5641694	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	558845	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5082849	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M2D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M19D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0674	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0565	pure
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	37237922	usd
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	begin to expire in 2038 through 2041
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	132513	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	132513	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3267961	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2239061	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	907392	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	622074	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4175893	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2861136	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4175893	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2861135	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	132513	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	93044	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	30382	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	780876	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	122154	usd
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9185104	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5649387	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.044	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.009	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.0006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Other EffectiveIncomeTaxRateReconciliationTaxSettlementsOther	-0.002	pure
CY2023	DFCO	Effective Income Tax Rate Reconciliation Gain On Expiration Of Accrued Tax Liability EffectiveIncomeTaxRateReconciliationGainOnExpirationOfAccruedTaxLiability	0.0000	pure
CY2022	DFCO	Effective Income Tax Rate Reconciliation Gain On Expiration Of Accrued Tax Liability EffectiveIncomeTaxRateReconciliationGainOnExpirationOfAccruedTaxLiability	0.0000	pure
CY2023	DFCO	Effective Income Tax Rate Reconciliation Stock Based Compensation EffectiveIncomeTaxRateReconciliationStockBasedCompensation	-0.041	pure
CY2022	DFCO	Effective Income Tax Rate Reconciliation Stock Based Compensation EffectiveIncomeTaxRateReconciliationStockBasedCompensation	-0.041	pure
CY2023	DFCO	Effective Income Tax Rate Reconciliation Nondeductible Interest EffectiveIncomeTaxRateReconciliationNondeductibleInterest	-0.201	pure
CY2022	DFCO	Effective Income Tax Rate Reconciliation Nondeductible Interest EffectiveIncomeTaxRateReconciliationNondeductibleInterest	0.008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.206	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.203	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009	pure

Files In Submission

Name	View Source	Status
dfco-20230630_cal.xml	Edgar Link	unprocessable
0001683168-23-007283-index-headers.html	Edgar Link	pending
0001683168-23-007283-index.html	Edgar Link	pending
0001683168-23-007283.txt	Edgar Link	pending
0001683168-23-007283-xbrl.zip	Edgar Link	pending
dalrada_ex3101.htm	Edgar Link	pending
dalrada_ex3201.htm	Edgar Link	pending
dalrada_i10k-063023.htm	Edgar Link	pending
dfco-20230630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
dfco-20230630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dalrada_i10k-063023_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dfco-20230630_lab.xml	Edgar Link	unprocessable
dfco-20230630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFCO
DALRADA FINANCIAL CORP Stock $dfco

2023 Q4 Form 10-K Financial Statement

#000168316823007283 Filed on October 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO DALRADA FINANCIAL CORP Stock $dfco

2023 Q4 Form 10-K Financial Statement

#000168316823007283 Filed on October 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO
DALRADA FINANCIAL CORP Stock $dfco